TC
IMMU

Truvestments Capital’s Immunomedics Inc IMMU Stock Holding History

Truvestments Capital’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,040
Closed -$14K – 743
2019
Q2 		$14K Hold
1,040
– – 0.01% 487
2019
Q1 		$20K Buy
+1,040
New +$16.8K 0.02% 402
2018
Q3 		$22K Buy
+1,040
New +$24.6K 0.01% 502

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Truvestments Capital's IMMU Position: Q3 2019 in Review

Truvestments Capital sold out of Immunomedics Inc (IMMU) in Q3 2019, closing a stake of 1,040 shares — an estimated $14K sold.

Truvestments Capital first reported a position in IMMU in Q3 2018 and held it in 3 quarters. The position peaked at $22K in Q3 2018. 208 funds tracked by Wall St. Rank hold IMMU as of Q3 2019.

  • Truvestments Capital reported no remaining Immunomedics Inc position as of Q3 2019 after selling out during the quarter.
  • Truvestments Capital sold 1,040 Immunomedics Inc shares in Q3 2019, an estimated $14K.
  • Truvestments Capital first reported a position in Immunomedics Inc in Q3 2018 and held it in 3 quarters.
  • Truvestments Capital's Immunomedics Inc position peaked at $22K in Q3 2018.
  • 208 funds tracked by Wall St. Rank held Immunomedics Inc as of Q3 2019.

Based on Truvestments Capital's 13F filing for Q3 2019, filed 10 Oct 2019.